FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017254004> ?p ?o ?g. }

• W2017254004 endingPage "322" @default.
• W2017254004 startingPage "317" @default.
• W2017254004 abstract "Purpose: Prolonged survival for patients with unresectable hepatocellular carcinoma (HCC) is consistently reported at lower than 6 months. Oxaliplatin has recently demonstrated activity in HCC. The objective of this study was to determine the response rate, survival, time to progression, and toxicity in patients with poor prognosis HCC when treated with oxaliplatin. Experimental Design: Patients were required to have measurable recurrent, metastatic or unresectable HCC, and to have previously been exposed to no more than 2 prior chemotherapy regimens. Karnofsky performance of 70% or above and adequate organ and hematologic function were required. All patients received treatment with oxaliplatin 100 mg/m2 on day 1 and 15 as a 2-hour intravenous infusion and were pretreated with antiemetics. Treatment was repeated every 28 days. Results: Thirty-six patients were enrolled and evaluated, although 6 expired before the first planned evaluation. Karnofsky performance status was 70/80/90/100% in 5/9/9/13 patients, respectively. The median time to progression was 2 months; median survival was 6 months. The 6-month overall survival was 55% (95% confidence interval 41%–74%), and the 6 month event-free survival was 11% (95% confidence interval 4%–28%). Conclusion: Single agent, oxaliplatin, has produced one partial response of good duration in 36 patients, but failed to meet the a priori criterion for promise in this trial. Sixteen patients were observed to have stable disease with a well tolerated toxicity profile. The combination of oxaliplatin and other agents should be considered to treat HCC in those patients with good functional status." @default.
• W2017254004 created "2016-06-24" @default.
• W2017254004 creator A5006718606 @default.
• W2017254004 creator A5018527792 @default.
• W2017254004 creator A5020831161 @default.
• W2017254004 creator A5022022603 @default.
• W2017254004 creator A5027495771 @default.
• W2017254004 creator A5030731004 @default.
• W2017254004 creator A5036091074 @default.
• W2017254004 creator A5036706377 @default.
• W2017254004 creator A5058936977 @default.
• W2017254004 creator A5064172508 @default.
• W2017254004 creator A5066487010 @default.
• W2017254004 creator A5071524213 @default.
• W2017254004 creator A5077178262 @default.
• W2017254004 creator A5084717592 @default.
• W2017254004 date "2008-08-01" @default.
• W2017254004 modified "2023-09-25" @default.
• W2017254004 title "Phase II Study of Oxaliplatin in Patients With Unresectable, Metastatic, or Recurrent Hepatocellular Cancer" @default.
• W2017254004 cites W109080479 @default.
• W2017254004 cites W1570300525 @default.
• W2017254004 cites W1968896032 @default.
• W2017254004 cites W1987555533 @default.
• W2017254004 cites W1988298330 @default.
• W2017254004 cites W1989885406 @default.
• W2017254004 cites W2010397777 @default.
• W2017254004 cites W2025081773 @default.
• W2017254004 cites W2028547579 @default.
• W2017254004 cites W2032553799 @default.
• W2017254004 cites W2056527566 @default.
• W2017254004 cites W2093311838 @default.
• W2017254004 cites W2119429559 @default.
• W2017254004 cites W2137828581 @default.
• W2017254004 cites W2147742546 @default.
• W2017254004 doi "https://doi.org/10.1097/coc.0b013e318162f57d" @default.
• W2017254004 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18845988" @default.
• W2017254004 hasPublicationYear "2008" @default.
• W2017254004 type Work @default.
• W2017254004 sameAs 2017254004 @default.
• W2017254004 citedByCount "37" @default.
• W2017254004 countsByYear W20172540042012 @default.
• W2017254004 countsByYear W20172540042013 @default.
• W2017254004 countsByYear W20172540042014 @default.
• W2017254004 countsByYear W20172540042015 @default.
• W2017254004 countsByYear W20172540042016 @default.
• W2017254004 countsByYear W20172540042019 @default.
• W2017254004 countsByYear W20172540042020 @default.
• W2017254004 countsByYear W20172540042021 @default.
• W2017254004 countsByYear W20172540042022 @default.
• W2017254004 crossrefType "journal-article" @default.
• W2017254004 hasAuthorship W2017254004A5006718606 @default.
• W2017254004 hasAuthorship W2017254004A5018527792 @default.
• W2017254004 hasAuthorship W2017254004A5020831161 @default.
• W2017254004 hasAuthorship W2017254004A5022022603 @default.
• W2017254004 hasAuthorship W2017254004A5027495771 @default.
• W2017254004 hasAuthorship W2017254004A5030731004 @default.
• W2017254004 hasAuthorship W2017254004A5036091074 @default.
• W2017254004 hasAuthorship W2017254004A5036706377 @default.
• W2017254004 hasAuthorship W2017254004A5058936977 @default.
• W2017254004 hasAuthorship W2017254004A5064172508 @default.
• W2017254004 hasAuthorship W2017254004A5066487010 @default.
• W2017254004 hasAuthorship W2017254004A5071524213 @default.
• W2017254004 hasAuthorship W2017254004A5077178262 @default.
• W2017254004 hasAuthorship W2017254004A5084717592 @default.
• W2017254004 hasConcept C121608353 @default.
• W2017254004 hasConcept C126322002 @default.
• W2017254004 hasConcept C141071460 @default.
• W2017254004 hasConcept C143998085 @default.
• W2017254004 hasConcept C2776694085 @default.
• W2017254004 hasConcept C2776907518 @default.
• W2017254004 hasConcept C2778019345 @default.
• W2017254004 hasConcept C2780962732 @default.
• W2017254004 hasConcept C29730261 @default.
• W2017254004 hasConcept C31760486 @default.
• W2017254004 hasConcept C44249647 @default.
• W2017254004 hasConcept C526805850 @default.
• W2017254004 hasConcept C71924100 @default.
• W2017254004 hasConcept C90924648 @default.
• W2017254004 hasConceptScore W2017254004C121608353 @default.
• W2017254004 hasConceptScore W2017254004C126322002 @default.
• W2017254004 hasConceptScore W2017254004C141071460 @default.
• W2017254004 hasConceptScore W2017254004C143998085 @default.
• W2017254004 hasConceptScore W2017254004C2776694085 @default.
• W2017254004 hasConceptScore W2017254004C2776907518 @default.
• W2017254004 hasConceptScore W2017254004C2778019345 @default.
• W2017254004 hasConceptScore W2017254004C2780962732 @default.
• W2017254004 hasConceptScore W2017254004C29730261 @default.
• W2017254004 hasConceptScore W2017254004C31760486 @default.
• W2017254004 hasConceptScore W2017254004C44249647 @default.
• W2017254004 hasConceptScore W2017254004C526805850 @default.
• W2017254004 hasConceptScore W2017254004C71924100 @default.
• W2017254004 hasConceptScore W2017254004C90924648 @default.
• W2017254004 hasIssue "4" @default.
• W2017254004 hasLocation W20172540041 @default.
• W2017254004 hasLocation W20172540042 @default.
• W2017254004 hasOpenAccess W2017254004 @default.
• W2017254004 hasPrimaryLocation W20172540041 @default.
• W2017254004 hasRelatedWork W1858240990 @default.

• next